Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
Clinical trial NCT03566017 · COMPLETED
Trial details
- NCT number
- NCT03566017
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-16
- Primary completion
- 2025-01-21
- Enrollment
- 97
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.